Table 2

Modelling of the association between CK and major bleeding

UnivariableORCI
CK3.17(1.69 to 5.89)
Sex*0.84(0.38 to 1.85)
Age1.08(1.03 to 1.13)
BMI0.95(0.87 to 1.02)
Ancestry†0.98(0.40 to 2.42)
Diabetes mellitus1.33(0.40 to 4.46)
Hypertension0.70(0.33 to 1.50)
Baseline SBP1.00(0.98 to 1.01)
Baseline haematocrit0.95(0.88 to 1.04)
Baseline creatinine0.93(0.81 to 1.07)
rt-PA vs placebo3.29(1.40 to 7.74)
Invasive vs conservative1.64(0.77 to 3.49)
Multivar. (full)BSEWaldORCI
CK1.100.3311.143.011.58 to 5.76
Sex− 0.270.420.400.770.34 to 1.75
Age0.080.0311.501.091.04 to 1.14
Diabetes mellitus0.340.640.291.410.40 to 4.93
rt-PA vs placebo1.230.447.803.431.44 to 8.15
Invasive vs conservative0.440.391.241.550.72 to 3.34
Constant−10.191.6637.500.00
Multivar. (restricted)
 CK 1.130.3311.923.101.63 to 5.90
 Age‡ 0.080.0211.241.091.04 to 1.14
 rt-PA vs placebo 1.240.447.883.451.45 to 8.18
 Constant − 9.901.6436.330.00
  • Modelling of the association between creatine kinase (CK) and major bleeding.

  • Parameter units are as in table 1. Baseline platelet count, and fibrinogen and fibrin(ogen) degradation products at 50 min or 12 hours after start therapy were not associated with major bleeding (OR 1; data not shown). Multivar., multivariable full and restricted models. Model parameters full (restricted) model: omnibus test of model coefficients χ2 34.2 (32.4) df 6 (3); −2 log likelihood 251 (253); Bayes information criterion 270 (262) Cox and Snell R square 0.02 (0.02); Nagelkerke R square 0.13 (0.12); Hosmer Lemeshow χ2 6.2 (9.8), df 8 (8); classification overall percentage 98.0 (98.0), n=1465 (1465) complete, unimputed cases. Bootstrapping OR was identical to the depicted outcomes (data not shown). Bold font indicates statistical significance.

  • *Women vs men.

  • †Non-white vs white.

  • ‡OR age per 10 years (under the assumption of linearity) is 2.27 (1.42 to 3.63). Including diuretic use at admission did not affect the final model. Substituting (log) CKmax during admission with (log) peak CK on day 1 yielded OR 2.64 (1.56 to 4.47) in the final model.

  • BMI, body mass index; SBP, systolic blood pressure; rt-PA, recombinant tissue-type plasminogen activator.